An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the adhesion of the test product when compared to the reference product following a single transdermal application.

Detailed Description
-----------------
The objective of this clinical trial is to evaluate the adhesion of the test product when compared to the reference product following a single transdermal application. The following evaluations will be assessed as yes or no: Cold flow (dark ring formed around the patch) Patch movement/displacement Patch wrinkling Residue formation (at patch application on the release liner and at patch removal on the skin) Safety and tolerability of a single dose application of a patch containing 18 mg rotigotine (Test) against a patch containing 18 mg rotigotine (Reference) will be evaluated in terms of vital signs and AEs. AEs and clinical tolerability will be monitored at all clinical trial visits. The safety evaluation will be based upon the review of the individual values (potentially clinically important abnormalities) and descriptive statistics (summary tables, graphics). As additional safety parameters for the clinical trial physical examination findings, clinical laboratory parameters, and 12-lead ECGs will be assessed at the screening and follow-up.

Official Title
-----------------
An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

Conditions
-----------------
Parkinson Disease

Intervention / Treatment
-----------------
* Drug: Rotigotine TTS (Test)
* Drug: Neupro (Reference)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with idiopathic Parkinson's Disease assessed as eligible for receiving 18 mg/IRR 8 mg/24 h rotigotine via the test and the reference product each on subsequent days in order to reach the dose of active substance at the individual routine medical care. Patients should be on a stable rotigotine dose of at least 8 mg/24 h for at least 1 week before screening. Exclusion Criteria: Current participation in another clinical trial, participation in another clinical study (i.e. last protocol specified visit) involving another IMP within at least 28 days prior to first application or previous participation in this clinical Trial History or presence of clinically significant dermatologic diseases or conditions, such as atopy, neurodermatitis, contact allergy, eczema, psoriasis, vitiligo, melanoma, squamous cell carcinoma. History or presence of any dermatological condition or skin sensitivity that could affect IMP Absorption History of clinically relevant (severe) hypersensitivity to the active pharmaceutical ingredient or substances of the same class or one of the excipients, clinically relevant allergy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Period 1: Rotigotine TTS (Test) - Period 2: Neupro (Reference)<br>For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h | Drug: Rotigotine TTS (Test)<br>* Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.<br>Drug: Neupro (Reference)<br>* Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.<br>|
| Active Comparator: Period 1: Neupro (Reference) - Period 2: Rotigotine TTS (Test)<br>For each period: an 18 mg transdermal patch to deliver 8 mg/24h will be applied for 24 h | Drug: Rotigotine TTS (Test)<br>* Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.<br>Drug: Neupro (Reference)<br>* Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patch Adhesion | Patch Adhesion will be measured as the percentage of area that remained adhered after 24 hours of patch application. | 24 hours in each Treatment Period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with cold flow | Cold flow is defined as dark ring formed around the patch | 24 hours in each Treatment Period | 
| Number of patients with patch movement/displacement |  | 24 hours in each Treatment Period | 
| Number of patients with patch wrinkling |  | 24 hours in each Treatment Period | 
| Number of patients with patch residue formation | Patch residue formation is assessed at patch application on the release liner and at patch removal on the skin. | 24 hours in each Treatment Period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
adhesiveness